Privo Technologies Announces Milestone in PRV211 Arm of CLN-004 Clinical Trial: Primary Endpoint Met; No Serious Adverse Events Reported

Key Highlights: Phase 1/2 safety cohort enrollment complete: Eight (8) patients with invasive oral cavity cancer treated in the PRV211 safety cohort Primary safety endpoint met: Safety assessed by clinical laboratory evaluations and/or clinical examination at 1-month post-surgery...